# Allison Luo

> Allison Luo, MD is the Chief Medical Officer of Mirador Therapeutics, a San Diego precision-medicine company that launched in 2024 with more than $400 million to attack immuno-fibrotic diseases using its Mirador360 development engine. A physician scientist with more than two decades in clinical development, she was CMO of Prometheus Biosciences before Merck bought it for $10.8 billion, and has since reassembled with that team to build Mirador. She sits on the board of Triveni Bio and has held medical-leadership roles across Ventyx, Biora, Iveric Bio and Bristol Myers Squibb.

- **Role:** Chief Medical Officer at Mirador Therapeutics
- **Organizations:** Mirador Therapeutics, Triveni Bio, Prometheus Biosciences, Ventyx Biosciences (Oppilan), Escalier Biosciences, Biora Therapeutics (Progenity), Iveric Bio (Ophthotech), Bristol Myers Squibb, Abbott Laboratories (AbbVie)
- **Nationality:** American
- **Education:** B.S. in Biochemistry, Northwestern University, M.D., Northwestern University, Drug Development Fellowship, Abbott Laboratories (AbbVie)
- **Known for:** Chief Medical Officer at Mirador Therapeutics, which launched in 2024 with more than $400 million, Former CMO of Prometheus Biosciences, acquired by Merck for $10.8 billion in 2023, Successfully completed two Phase 3 clinical studies while VP of Clinical Development at Iveric Bio

## Career timeline

- **Early career** — Drug development fellowship at Abbott Laboratories (now AbbVie)
- **2010s** — Bristol Myers Squibb, overseeing programs including Orencia and eldelumab
- **2010s** — VP of Clinical Development at Ophthotech (Iveric Bio); completed two Phase 3 studies
- **2010s** — SVP of Clinical Development for Gastroenterology at Progenity (Biora Therapeutics)
- **2010s-2020s** — Chief Medical Officer of Escalier and Oppilan (Ventyx Biosciences)
- **2021-2023** — Chief Medical Officer of Prometheus Biosciences, acquired by Merck for $10.8 billion
- **2023-12** — Appointed to the Board of Directors of Triveni Bio
- **2024** — Named Chief Medical Officer of Mirador Therapeutics at its $400M+ launch
- **2026-01** — Mirador closes $250M Series B, bringing total funding to roughly $650M

## Achievements

- Chief Medical Officer at Mirador Therapeutics, which launched in 2024 with more than $400 million
- Former CMO of Prometheus Biosciences, acquired by Merck for $10.8 billion in 2023
- Successfully completed two Phase 3 clinical studies while VP of Clinical Development at Iveric Bio
- More than two decades of clinical development experience across immunology, gastroenterology and ophthalmology
- Board member of Triveni Bio since December 2023
- Oversaw programs for Orencia and eldelumab at Bristol Myers Squibb

## Latest updates

- **2026-01** — Mirador Therapeutics closed a $250 million Series B to accelerate its multi-asset immuno-fibrotic clinical pipeline, bringing total funding to roughly $650 million.
- **2024** — Joined Mirador Therapeutics as Chief Medical Officer at its launch with more than $400 million in financing.

## Links

- Website: https://miradortx.com
- LinkedIn: https://www.linkedin.com/in/allisonluo/

---

Profile page: https://yespress.io/allison-luo
Published by YesPress — https://yespress.io
Last updated: 2026-07-02